Tag: nasdaq:eyen

June 4, 2019

Eyenovia Enrolls First Patient in Phase 3 Study for Progressive Myopia

Eyenovia (NASDAQ:EYEN) has announced it has initiated its MicroPine Phase 3 program with the first patient enrolled in its CHAPERONE...
February 25, 2019

Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis

Eyenovia (NASDAQ:EYEN) has announced positive results from its second MicroStat Phase III study called MIST-2. As quoted in the press...
February 6, 2019

Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

Eyenovia (NASDAQ:EYEN) has announced that the US Food and Drug Administration has accepted its Investigational New Drug (IND) application to...
January 1, 2019

An Investor’s Guide to Clinical Trials

Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the...
December 3, 2018

Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

Eyenovia (NASDAQ:EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first...
November 29, 2018

Eyenovia Announces Publication of its PG21 Phase II Trial Results

Eyenovia (NASDAQ:EYEN) announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with...